The importance of the Covid-19 vaccine in patients suffering from adult autosomal dominant polycystic kidney disease (ADPKD)

Authors

  • Maria Teresa Sciarrone Alibrandi University Vita Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milano - Italy
  • Giancarlo Joli University Vita Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milano - Italy
  • Rodolfo F. Rivera U.O. Nefrologia e Dialisi, Ospedale di Desio - ASST - Brianza, Desio - Italy
  • Elena Brioni University Vita Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milano - Italy
  • Romina Bucci University Vita Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milano - Italy
  • Marta Vespa University Vita Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milano - Italy

DOI:

https://doi.org/10.33393/gcnd.2021.2256

Keywords:

ADPKD patients, SARS-CoV-2 (Covid-19), Vaccine

Abstract

The SARS-CoV-2 (Covid-19) infection affected about 106 million people worldwide and the total amount of casualties now sits at a staggering 2 millions.

Chronic Kidney Disease (CKD) emerged as the first risk factor in worst patients, not considering old age. Kidney disease and acute kidney injury have been correlated with a higher chance of death. This combination of CKD and higher Covid-19 related mortality requires immediate response from a prevention point of view at first and then from a therapeutic one.

There is not a clear relation between Covid-19 and ADPKD. What can be inferred is the following: Covid uses the ACE2 receptors on cell membranes to “lock on” its target. It is well-established in fact that the RAAS is more active in ADPKD patients and it may represent an additional risk factor for these patients.

At the moment three Covid-19 vaccines have been approved, and two of them have been already administered, such as Pfizer BioNTech and Moderna, sharing the same mechanism. AstraZeneca released a third option. All of them are completely safe and reliable, each one with its own feature.

Therefore, considering how delicate ADPKD patients are, vaccination is strongly recommended.

References

  1. Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk Factors for COVID-19. Infez Med. 2020;28(4):469-474. PMID:33257620
  2. Adapa S, Chenna A, Balla M, et al. COVID-19 pandemic causing acute kidney injury and impact on patients with chronic kidney disease and renal transplantation. J Clin Med Res. 2020;12(6):352-361. https://doi.org/10.14740/jocmr4200 PMID: 32587651
  3. Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the kidney: from epidemiology to clinical practice. J Clin Med. 2020;9(8):2506. Online https://doi.org/10.3390/jcm9082506 PMID: 32759645
  4. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. https://doi.org/10.1002/path.1570 PMID:15141377
  5. Stephens JR, Stümpfle R, Patel P, et al. Analysis of Critical Care Severity of Illness Scoring Systems in Patients With Coronavirus Disease 2019: A Retrospective Analysis of Three U.K. ICUs. Crit Care Med. 2021;49(1):e105-e107. https://doi.org/10.1097/CCM.0000000000004674PMID:32991357
  6. Fominskiy EV, Scandroglio AM, Monti G, et al; COVID-BioB Study Group. Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. Blood Purif. 2021;50(1):102-109. https://doi.org/10.1159/000508657 PMID:32659757
  7. Quintaliani G, Reboldi G, Di Napoli A, et al; Italian Society of Nephrology COVID-19 Research Group. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J Nephrol. 2020;33(4):725-736. https://doi.org/10.1007/s40620-020-00794-1 PMID:32621109
  8. Sciarrone Alibrandi MT, Vespa M. Kidney, ADPKD and Covid-19: the double role of renal fragility. G Clin Nefrol E Dialisi. 2020;32(1):99-101. https://doi.org/10.33393/gcnd.2020.2165
  9. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMID:33301246
  10. Anderson EJ, Rouphael NG, Widge AT, et al; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427-2438. https://doi.org/10.1056/NEJMoa2028436 PMID:32991794
  11. Glanville D. COVID-19 vaccines: key facts. European Medicines Agency. 2020. Online https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-key-facts
  12. Vaccini a mRNA | Agenzia Italiana del Farmaco. Online https://aifa.gov.it/vaccini-mrna
  13. Vaccini a vettore virale | Agenzia Italiana del Farmaco. Online https://aifa.gov.it/vaccini-vettore-virale
  14. Glanville D. EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU. European Medicines Agency. 2021. Online https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu
  15. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for Covid-19. Front Immunol. 2020;11:585354. Online https://www.frontiersin.org/articles/10.3389/fimmu.2020.585354/full
  16. Pinho AC. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU. European Medicines Agency. 2021. Online https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu
  17. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. https://doi.org/10.1016/S0140-6736(20)32623-4 PMID:33306990
  18. Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID:33306989

Most read articles by the same author(s)

1 2 > >>